Ruxolitinib Viatris (ruxolitinib hemifumarate)

Where it stands

Ruxolitinib Viatris (ruxolitinib hemifumarate) is authorised in the EU. The CHMP adopted a positive opinion on 2026-07-23, and the European Commission decision followed on 2026-09-18. The marketing authorisation holder is Viatris Limited. Both milestones are recorded as official.

The interval between opinion and EC decision was about eight weeks (57 days). In the centralised procedure, the Commission decision converts the CHMP opinion into a marketing authorisation valid in all EU Member States, plus Iceland, Liechtenstein and Norway.

The authorised indications cover three areas. In myelofibrosis, the product is for disease-related splenomegaly or symptoms in adults with primary myelofibrosis, post-polycythaemia vera myelofibrosis or post-essential thrombocythaemia myelofibrosis. In polycythaemia vera, it is for adults who are resistant to or intolerant of hydroxyurea. In graft versus host disease (GvHD), it covers acute GvHD in adults and paediatric patients aged 28 days and older, and chronic GvHD in adults and paediatric patients aged 6 months and older. In both GvHD indications, patients must have had an inadequate response to corticosteroids or other systemic therapies.

Regulatory pathway and designations

The only designation in the records is "Generic". In general terms, a generic medicine is authorised on the basis of its quality and its demonstrated equivalence to an already-authorised reference medicine, rather than a full stand-alone clinical development programme. The records do not name the reference product or the specific legal basis, so those details should be confirmed from the EPAR or the product information.

The records show the CHMP opinion and EC approval but no clock-stop details, submission date or procedural timetable. They also show no orphan, PRIME or conditional-approval status. Absence from the records should not be read as confirmation that no such status exists.

The indication wording is detailed and includes a cross-reference to section 5.1 of the product information for the GvHD indications. The records do not say whether this wording matches the reference product's, or whether any indications were carved out. They list all three therapeutic areas as covered.

Safety and pharmacovigilance

The records contain no safety data, risk management plan details, additional monitoring status or post-authorisation commitments for this product, so no safety assessment can be made from them. Professionals should consult the authorised product information and the EPAR once published.

What to watch

The first item is the publication of the EPAR and the final product information. These would confirm the reference product, the exact indication wording, and any safety or risk-minimisation measures. The records do not state when they will appear.

The second is commercial availability. The records give no launch dates, pricing or reimbursement information. In general, national pricing, reimbursement and market-entry timing in each Member State are separate from the EC decision and depend on national procedures and any applicable intellectual property or regulatory protections. None of these are covered in the records.

Finally, for a centrally authorised product, any later variations, safety updates or changes to the marketing authorisation will be reflected in the EU product information. None are recorded here.